🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 83 of 173

  1. US 9539341

    Methods and compositions for targeting adipose cells in mammals

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9539340

    Bladder cancer specific ligand peptides

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9539321

    HMGB1-derived peptides enhance immune response to antigens

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9539300

    Modulating disease through genetic engineering of plants

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9539283

    Citrate-rich calcium-magnesium supplement and uses thereof

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9539231

    Method for treating triple-negative breast cancer using AMPI-109

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9532994

    Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9534033

    Targeted interferons demonstrating potent apoptotic and anti-tumor activities

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9535076

    Methods and compositions for eliciting an amyloid-selective immune response

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9533045

    Photothermal therapy using magnetic nanoparticles

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9533025

    Method for treating chemotherapy-induced male infertility

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9527919

    High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9526760

    LEDGF peptides and formulations thereof for treatment of degenerative disorders

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9527884

    Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9527917

    Nucleic acid encoding anti-OX40 antibodies

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9527889

    RFamide-related peptides and methods thereof

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9527878

    Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9527868

    ETP derivatives

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9526786

    Thermostabilization of proteins

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9526824

    Nanochanneled device and related methods

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9529005

    Modulating bacterial MAM polypeptides in pathogenic disease

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9529001

    Methods of diagnosing and treating autism

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9528994

    Target of the phosphoinositide 3-kinase pathway

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9526747

    Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9526737

    Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9522241

    Controlled release nanoparticulate matter delivery system

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9523675

    Insect repellent and attractants

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9523079

    Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9522289

    Selective fat removal using photothermal heating

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9522179

    Compositions and methods for modulating cardiac conditions

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9523695

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9517229

    Treatment of breast cancer

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9517241

    Amelioration of intestinal fibrosis and treatment of Crohn's disease

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9517230

    Small molecule RNase inhibitors and methods of use

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9517240

    Methods and compositions for cancer prevention and treatment

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9518090

    Compositions and methods for treating hepatitis B

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9517270

    Lipocationic polymers and uses thereof

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9511152

    Multicolored pH-activatable fluorescence nanoplatform

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9512481

    Polymorphisms in the PDE3A gene

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9512406

    Generating hepatocytes

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9512138

    Compositions and methods for treating cancer

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9511115

    Pharmaceutical compositions for treating or preventing bone conditions

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9511038

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9512401

    B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9512125

    Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9511039

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9511020

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9512212

    Bispecific antibody fragments for neurological disease proteins and methods of use

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.